Travere Therapeutics, Inc. closed fiscal year 2025 with $605.2M in total assets, $490.4M in total liabilities and $114.8M in shareholder equity. Total assets rose 1.9% from the prior fiscal year. The table below carries 15 fiscal years, from 2012 to 2025, and the quarters Travere Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
TVTX Balance Sheet by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-Q | FY2310-K | FY22Filing | FY2110-K | FY2010-K | FY1910-K | FY18Filing | FY17Filing | FY1610-K | FY15Filing | FY1410-K | FY1310-K | FY1210-K | FY1210-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $605.2M+1.9% | $594.1M-24.7% | $788.9M+17.3% | $672.6M-13.4% | $776.6M+27.9% | $607.4M+0.4% | $604.8M-14.7% | $709.2M+36.3% | $520.3M-0.9% | $525.3M+2.5% | $512.3M+278.1% | $135.5M+560.9% | $20.5M+757.2% | $2.4M | $4K |
| Total Liabilities | $490.4M-8.4% | $535.0M-9.0% | $588.1M-6.6% | $629.7M+32.7% | $474.5M+19.8% | $396.2M+3.3% | $383.6M-1.9% | $390.9M+72.0% | $227.2M+4.5% | $217.5M+2.5% | $212.3M+22.9% | $172.7M+330.0% | $40.2M+592.6% | $5.8M | $67K |
| Total Equity | $114.8M+94.4% | $59.1M-70.6% | $200.8M+368.6% | $42.9M-85.8% | $302.1M+43.0% | $211.2M-4.5% | $221.2M-30.5% | $318.3M+8.6% | $293.1M-4.8% | $307.8M+2.6% | $300.0Mn/m | -$37.3Mn/m | -$19.7Mn/m | -$3.4M | -$63K |
TVTX Balance Sheet by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $848.2M+57.5% | $799.4M+43.9% | $555.2M+1.2% | $605.2M+1.9% | $538.6M+6.8% | $555.3M+0.8% | $548.8M-17.3% | $594.1M-24.7% | $504.4M-39.4% | $551.1M-25.2% | $663.5M-17.9% | $788.9M+17.3% |
| Total Liabilities | $825.6M+77.6% | $774.8M+48.3% | $456.5M-11.5% | $490.4M-8.4% | $465.0M-13.1% | $522.6M-2.5% | $516.0M-12.5% | $535.0M-9.0% | $534.9M-3.3% | $536.0M-13.5% | $589.5M-4.8% | $588.1M-6.6% |
| Total Equity | $22.6M-69.3% | $24.5M-25.1% | $98.7M+200.8% | $114.8M+94.4% | $73.6Mn/m | $32.7M+116.2% | $32.8M-55.7% | $59.1M-70.6% | -$30.5M-110.9% | $15.1M-87.0% | $74.1M-60.8% | $200.8M+368.6% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Travere Therapeutics, Inc. financials
Frequently Asked Questions
Travere Therapeutics, Inc. closed fiscal year 2025 with $605.2M in total assets, $490.4M in total liabilities and $114.8M in shareholder equity.
Travere Therapeutics, Inc. (TVTX) total assets rose by 1.9% year over year, from $594.1M to $605.2M in fiscal year 2025.
Across the 15 fiscal years this page covers, Travere Therapeutics, Inc. (TVTX) total assets went from $4K in fiscal year 2012 to $605.2M in fiscal year 2025.
Travere Therapeutics, Inc. (TVTX) reported $848.2M in total assets in Q3 2026. This represents an increase of 57.5% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Travere Therapeutics, Inc. (TVTX) reported on that line in every period on record.